Dr. Natalia Isabel Moguillansky, MD

Dr. Moguillansky practices at UF Health Shands Hospital in Gainesville, Florida, part of UF Health.

Dr. Moguillansky's NPI, 1891002697, was assigned on September 1, 2010. Dr. Moguillansky graduated from University of Buenos Aires in 2004. Dr. Moguillansky holds Florida license ME110901.

Dr. Moguillansky's primary practice is UF Health Shands Hospital, at 1600 SW Archer Rd, Gainesville, FL 32610 in Alachua County. The practice phone is (352) 265-8000.

Dr. Moguillansky's primary practice is UF Health Shands Hospital in Gainesville, Florida, part of UF Health. Dr. Moguillansky is also affiliated with UF Health Spanish Plaines Hospital. The medical group on file is UF Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moguillansky practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Moguillansky's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Moguillansky is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Moguillansky's licenses on file in 2 states: Florida and Pennsylvania.

CMS data shows 2,337 Medicare services from Dr. Moguillansky across 19 procedure codes in 2024, for 859 Medicare patients. Medicare paid $79,425 for them.

CMS counts 859 Medicare patients who saw Dr. Moguillansky in 2024. The largest group is 65 to 74, with 395 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Moguillansky's median patient age at 72, with 61% women.

In 2024, Dr. Moguillansky wrote 2,810 Medicare Part D claims for 432 patients. 43% of them were for generic drugs. CMS names the drug for 2,672 of them, across 33 drugs with 11 or more claims each, at $3,113,726 in total drug cost. In 2023, CMS named 2,298 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Moguillansky for performance year 2024, reported individually. Dr. Moguillansky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Moguillansky as offering telehealth.

Dmand AI links 9 papers to Dr. Moguillansky, published from 2017 to 2024. 2023 was the busiest year, with 3. Dr. Moguillansky has published most often in Cureus. Dr. Moguillansky's most frequent co-authors are Diego Moguillansky, MD, Ali Ataya, MD and Mark Steven Bleiweis, MD.

CMS Open Payments shows 2 general payments to Dr. Moguillansky from 1 drug or device company from 2018 to 2020. Food and beverage make up the largest share, 92% of the total. AstraZeneca Pharmaceuticals LP paid the most, $137.

Dmand AI lists 1 award for Dr. Moguillansky, most recently CMS Stage 1 EHR in 2013.

Dr. Moguillansky graduated from University of Buenos Aires in 2004.

Dr. Moguillansky is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.